Heparan Sulfate in the Tumor Microenvironment

被引：22

作者：

Bartolini, Barbara ^{[1
]}

Carava, Elena ^{[1
]}

Caon, Ilaria ^{[1
]}

Parnigoni, Arianna ^{[1
]}

Moretto, Paola ^{[1
]}

Passi, Alberto ^{[1
]}

Vigetti, Davide ^{[1
]}

Viola, Manuela ^{[1
]}

Karousou, Evgenia ^{[1
]}

机构：

[1] Univ Insubria, Dept Med & Surg, Varese, Italy

来源：

TUMOR MICROENVIRONMENT: EXTRACELLULAR MATRIX COMPONENTS - PT A | 2020年 / 1245卷

关键词：

Heparan sulfate; Tumor; Glycosaminoglycan; Proteoglycan; UDP-sugars; Heparanase; Extracellular matrix; Cancer; Cell growth; Invasion; Adhesion; Metastasis; Inflammation; Angiogenesis; Growth factor; FIBROBLAST-GROWTH-FACTOR; MAMMALIAN HEPARANASE; COLLAGEN-XVIII; MANNOSE; 6-PHOSPHATE; CANCER METASTASIS; FACTOR-BINDING; CELL-ADHESION; BREAST-CANCER; PROTEOGLYCANS; EXPRESSION;

D O I：

10.1007/978-3-030-40146-7_7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The biology of tumor cells strictly depends on their microenvironment architecture and -composition, which controls the availability of growth factors and signaling molecules. Thus, the network of glycosaminoglycans, proteoglycans, and proteins known as extracellular matrix (ECM) that surrounds the cells plays a central role in the regulation of tumor fate. Heparan sulfate (HS) and heparan sulfate proteoglycans (HSPGs) are highly versatile ECM components that bind and regulate the activity of growth factors, cell membrane receptors, and other ECM molecules. These HS binding partners modulate cell adhesion, motility, and proliferation that are processes altered during tumor progression. Modification in the expression and activity of HS, HSPGs, and the respective metabolic enzymes results unavoidably in alteration of tumor cell microenvironment. In this light, the targeting of HS structure and metabolism is potentially a new tool in the treatment of different cancer types.

引用

页码：147 / 161

页数：15

共 128 条

[91] The immunomodulatory role of tumor Syndecan-1 (CD138) on ex vivo tumor microenvironmental CD4+ T cell polarization in inflammatory and non-inflammatory breast cancer patients [J].